An increase in peripheral ICOS+CD4+ T cells has been also shown as a good clinical ICB responses in patients with hormone-responsive advanced breast cancer, which were treated with the anti-CTLA4 tremelimumab in combination with exemestane (Vonderheide et al., 2010). This evidence concerns the gene CTLA4 and breast carcinoma.